4 Healthcare Stock Stories for Tuesday Investment Wellness
Sanofi-Aventis (NYSE:SNY): Closing price $49.26
Sanofi reports that the European Commission has given the nod to its candidate, Lemtrada, for adults suffering with relapsing remitting multiple sclerosis. Prior to this, the European Medicines Agency’s Committee for Medicinal Products for Human Use had recommended the approval of Lemtrada in June, issuing a positive opinion on Lemtrada based on two pivotal phase III trials, which were finished in 2011. In the first evaluation, CARE-MS I, Lemtrada attained the first primary endpoint. Results indicated that treatment with two annual cycles of Lemtrada versus Rebif resulted in a 55-percent reduction in the relapse rate over the two-year span of the study.